Original editorial illustration, not a study figure or measurement. Study discussed: Sullivan and colleagues, Climacteric, 2026.
Two bottles sit beside each other. Both promise menopause support, yet their ingredients may be entirely different. Does a shared label imply similar effects? An analysis of 201 products available online in the UK primarily reveals the diversity of that market. It was not a trial testing whether the products helped women.
This distinction matters both when shopping and when reading headlines. “Supplements were analysed” may sound like “a treatment was tested”, but these describe different activities. The researchers examined product information, not changes in hot flushes, sleep or quality of life. Their work helps us ask better questions; it does not supply a simple list of good and bad brands.
What came under scrutiny?
Poppy Sullivan, Anne-Marie Boylan and Joyce Catherine Harper searched nine major retailers and Google Shopping. Data collection took place between May and July 2025. The paper appeared online in Climacteric on 10 September 2026. Both dates matter: publication followed the market snapshot, and the products on offer may since have changed.
Products qualified if their name or description referred to menopause. After selection and removal of duplicates, 577 product results yielded 201 unique products. These included different formats, not just tablets. Ingredients, doses and prices came from retailer or manufacturer websites. The researchers did not measure the contents of capsules in a laboratory.
Nor was this a complete census of the UK market. The search aimed to approximate what a consumer might encounter online. Restrictions on search terms and the number of results reviewed affected product selection. The appropriate description is therefore “in this sample of the UK online offering”, not “in all supplements worldwide” or “in the Polish market”.
One label, different formulations
Within the sample, herbs appeared in 80.1% of products, vitamins in 76.6% and phytoestrogens in 74.1%. These percentages should not add up to one hundred: a single product could include ingredients from several categories. The categories describe formulations, not separate patient groups or distinct mechanisms with established clinical benefits.
Vitamin B6 was listed in 139 of the 201 products, or 69.2%. Zinc appeared in 48.8% and magnesium in 47.3%. Sage and red clover were common plant ingredients. However, popularity does not explain why an ingredient would help a particular person or which treatment outcome should be monitored.
This is not a league table. The most common ingredient does not thereby become the best, and a rare ingredient is not automatically worthless. The study describes what was offered and declared. Moving from the presence of a substance to a claim about improved health requires a different kind of evidence, which this project does not provide.
A longer list is not an answer
More than ten active ingredients were listed in 61.7% of the products. To a shopper, a long label may suggest a comprehensive solution: perhaps more ingredients address more problems. That is an intuitive impression, not a clinical finding. This audit did not compare women taking simpler formulations with women taking more complex mixtures.
It cannot therefore show that more ingredients improved outcomes. Counting ingredients alone cannot establish harm either. Two questions deserve separate answers: what does the product contain, and what is known about using that particular product for a particular purpose? The label addresses the first. The second usually requires finding and critically reading research.
Imagine a hypothetical advertisement for a mixture that places a scientific reference beside one ingredient. That does not establish whether researchers tested the finished mixture, the same dose, a similar duration or comparable participants. This example does not identify a brand from the audit. It illustrates how a genuine reference can sit alongside a broader promise that the reference itself does not support.
What does the number beside a dose mean?
The researchers recorded substantial variation in declared doses. Complete information was not available for every product. That already limits comparisons: a missing value in a dataset does not mean the substance was absent. It means the relevant information could not be obtained from the source used. Missing data are not the same as a measured zero.
Botanical ingredients posed another difficulty. Some manufacturers reported the mass of an extract; others gave an equivalent amount of the whole plant. The authors did not compare these doses because numbers attached to similar names were not directly comparable. A larger number on the label need not represent more of the same substance in the same form.
The percentage of a nutrient reference value, or NRV, also needs careful interpretation. It is not a percentage measure of effectiveness. An NRV is not a safe upper intake limit, so exceeding it does not by itself establish toxicity. This article sets no doses or safety thresholds: doing so would require a separate assessment of the indication, product and current guidance.
Price measures spending, not treatment outcomes
Estimated costs ranged from £1.50 to £95 for thirty days of use. These are prices from the UK offering studied, not a current price list for Poland or elsewhere. The cost figure included 200 products: for one liquid product, the researchers could not determine how many days a bottle would last. Even an apparently simple price comparison needs a clear denominator.
The price range does not identify the best value in treatment. To assess value, we would need to know the benefit, and symptom improvement was not measured here. A more expensive product was not shown to be more effective. A cheaper one was not shown to be equivalent. The findings justify asking about costs, but do not rank cost-effective treatments.
What could the researchers not establish?
The analysis relied on public product information, which can contain omissions or errors. Product quality, ingredient bioavailability and regulatory compliance were not assessed. The search was conducted once, while the market changes quickly. A product available then may now have a different formulation, price or availability. The paper therefore cannot replace checking a current label.
No women were followed as patients in this study. It provides no direct measurements of adverse-event frequency, interactions or quality-of-life improvement after taking a mixture. The discussion considers previous literature, but that does not turn this project into a treatment trial. “They tested 201 products and none worked” would be an unjustified conclusion.
Five questions before choosing a product
The following is an editorial aid for discussion, not a validated quality test or a personalised purchasing recommendation. Its purpose is to organise information that can get lost among claims on packaging.
- Which problem am I trying to address? General “menopause support” does not specify a symptom or an outcome that would indicate meaningful change. Naming the goal helps establish whether the evidence cited actually concerns it.
- Do I understand the full composition and dose description? Distinguish a serving from one capsule, and an extract from a whole-plant equivalent. If the label does not clarify this, the information remains uncertain rather than automatically favourable or unfavourable.
- What was studied in the cited paper? An ingredient and a finished formulation are not the same research subject. A laboratory measurement or market analysis likewise cannot substitute for assessing symptoms in patients.
- What information is missing? Ask not only about the hoped-for benefit but also about the limits of the evidence and what was not assessed. An honest answer can include “we do not know”.
- Does my clinician know all the products I use? A list of names and ingredients helps a discussion of the overall care plan. Do not replace prescribed treatment independently simply because a package promises broad support.
The main takeaway
When reading health information, distinguish the researchers’ question from your own expectations. A woman may chiefly want to know whether she will sleep better. A market researcher may ask how frequently a particular ingredient appears on labels. Both are reasonable questions, but answering the second does not resolve the first. This is a boundary of the audit’s use, not a flaw in the idea of conducting it.
Not measuring clinical effects does not make the research unnecessary. It organises the product landscape, reveals difficulties in comparing formulations and highlights questions for further investigation. Its usefulness diminishes when a market description becomes a promise of treatment or proof of ineffectiveness. Good education retains the information without extending the conclusion beyond what was measured.
The label “for menopause” grouped products with very different declared ingredients and costs. It did not describe one uniform intervention. The study makes that diversity visible but does not settle the effectiveness of individual formulations. Its most useful application is more careful reading of labels and sources, rather than blanket enthusiasm for supplements or blanket condemnation.
If you are considering a product, bring its current ingredient list to a consultation and explain what you hope it will achieve. Your situation and a specific problem should be the starting point, not the length of the label. This article supports that conversation; it is not a guide to changing treatment or choosing a dose independently.